Buch

---

Übersicht

---

Verlag	:	Springer Netherland
Buchreihe	:	Developments in Nuclear Medicine (Bd. 26)
Sprache	:	Englisch
Erschienen	:	30. 11. 1995
Seiten	:	360
Einband	:	Gebunden
Höhe	:	235 mm
Breite	:	155 mm
Gewicht	:	976 g
ISBN	:	9780792337164
Sprache	:	Englisch

---

Inhaltsverzeichnis

---

one: Introduction.- 1. Drug development and positron emission tomography.- 2. Positron emission tomography: Basic principles and potential interest for pharmacological studies.- 3. Is PET a tool for drug evaluation?.- two: Psychiatry.- 4. PET in neuropsychiatric drug development.- 5. Radioligand disposition and metabolism - Key information in early drug development.- 6. PET studies in the early clinical development of a new antipsychotic.- 7. PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugs.- 8. Is the 5-HT2-receptor a target for antipsychotic drug action? PET studies on dopamine (D2) and serotonin (5-HT2) receptor occupancy in patients and healthy subjects.- 9. Preclinical development of a radioligand for the study of central 5-HT1A receptors with PET-[11C]WAY-100635.- 10. Comparative in vivo and in vitro selectivity of zolpidem for ? (Benzodiazepine) modulatory site subtypes.- 11. Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer’s disease in normal volunteers?.- three: Neurology.- 12. PET evaluation of drug treatment in ischemic stroke and Alzheimer’s disease.- 13. PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapy.- 14. Pharmacokinetics: Kinetic modelling of MAO inhibitors and D2 antagonists.- 15. Brain activation under drug treatment.- 16. Modifying the progression of Parkinson’s disease.- 17. COMT inhibition: Pharmacology of tolcapone and 6-[18F]-Fluoro-L-Dopa (FDOPA) PET results.- 18. Interaction of Lisuride with dopaminergic receptors.- 19. Lisuride and [C-ll]-raclopride interaction at the D2 receptor site.- four: Cardiology.- 20. Drug design in cardiology:The pharmaceutical industry point of view.- 21. Myocardial receptors and their interaction with cardiovascular drugs.- 22. The pathophysiological background of cardiovascular diseases and its impact on diagnosis and treatment.- 23. Effect of cardiotonic drugs on myocardial oxygen consumption and efficiencyas assessed by 11C-acetate and PET.- 24. Integration of new and classical techniques in drug development. PET application to Propionyl-L-carnitine pharmacokinetic study.- five: Oncology.- 25. The view of the EORTC new drug development office on PET in (pre)clinical trials of anticancer drugs.- 26. Bottlenecks in anticancer drug discovery and development: In vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET.- 27. Radiolabeled anticancer drugs for in vivo pharmacokinetic studies by PET.- 28. The use of radiolabeled anticancer drugs in phase I/II clinical trials and the assessment of therapeutic efficacy of new agents using PET.- 29. Kinetics and applications of F-18-fluorouracil in colorectal tumors.- six: Miscellaneous.- 30. The disposition of a new drug propellant (HFA 134a) in humans studied by fluorine-18 labelling and whole-body ?-counting.- 31. Preclinical characterisation of radiolabeled idoxifene.

Deine Buchhandlung

---